Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
...52-year-old female patient with EGFR-mutated stage IV lung adenocarcinoma, who achieved a partial response (PR) to the treatment of gefitinib and osimertinib after acquiring EGFR exon 20 p.T790M-trans-C797S at osimertinib failure.
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.